Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.49 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229678 | 0.91 | MAPK14 (0.51) | MAPK14MAPK11MAPK13MAPK12LRRK2 | |
| SCHEMBL12229737 | 0.84 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12LRRK2 | |
| SCHEMBL2537333 | 0.81 | MAPK14 (0.84) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL2540595 | 0.80 | LRRK2 (0.55) | MAPK14MAPK11MAPK13MAPK12LRRK2 | |
| SCHEMBL12251205 | 0.80 | LRRK2 (0.56) | MAPK14MAPK11MAPK13MAPK12LRRK2 | |
| SCHEMBL12229701 | 0.79 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12229806 | 0.79 | MAPK14 (0.70) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL12229840 | 0.79 | MAPK14 (0.82) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL2543274 | 0.78 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12MAP3K14 | |
| SCHEMBL14424008 | 0.78 | MAPK14 (0.63) | MAPK14MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406875-B1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL MYERS SQUIBB CO (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8044040-B2 | e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044040-B2 | e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044040-B2 | e.g. 3-{3-Cyano-6-[(2,2-dimethyl-propyl)-methyl-amino]-5-fluoro-pyridin-2-ylamino}-N-methoxy-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
| US-7253174-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253174-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253174-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060276488-A1 | N-heterocyclic inhibitors of TNF-alpha expression | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-07 | — | — | US | disclosed |
| US-20030139435-A1 | N-heterocyclic inhibitors of TNF-alpha expression | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015185-A1 | N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION | TNF, RELA, NFKBIA | MAPK14 113/4885MAPK11 140/4885MAPK13 127/4885 |
| US-20030139435-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, TNFRSF1A | MAPK14 99/4885MAPK11 122/4885MAPK13 112/4885 |
| US-20060276488-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | MAPK14 113/4885MAPK11 140/4885MAPK13 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.